Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Mads Faurby"'
Publikováno v:
ESC Heart Failure, Vol 11, Iss 1, Pp 54-64 (2024)
Abstract Aims We aimed to examine cardiovascular events (stroke and myocardial infarction [MI]), mortality, early retirement and economic costs over 5 years in people with chronic heart failure (CHF) and matched controls in Sweden. Methods and result
Externí odkaz:
https://doaj.org/article/c23747a09ef14e5eae66b6bc5ecce985
Publikováno v:
BMC Cardiovascular Disorders, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Aim To examine direct and indirect costs, early retirement, cardiovascular events and mortality over 5 years in people with atherosclerotic cardiovascular disease (ASCVD) and matched controls in Sweden. Methods Individuals aged ≥ 16 years
Externí odkaz:
https://doaj.org/article/5637987885cd468780e83da89a807c5c
Autor:
Marc Evans, Joanna de Courcy, Elisabeth de Laguiche, Mads Faurby, Christiane Lundegaard Haase, Kasper Sommer Matthiessen, Adam Moore, Jonathan Pearson-Stuttard
Publikováno v:
International Journal of Obesity.
Background Obesity-related complications (ORCs), such as type 2 diabetes (T2D) and cardiovascular disease, contribute considerably to the clinical and economic impacts of obesity. To obtain a holistic overview of health and weight management attempts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d7e078e3059ef506e684cd1f519d816
https://doi.org/10.1038/s41366-023-01325-1
https://doi.org/10.1038/s41366-023-01325-1
Publikováno v:
Diabetes, Obesity & Metabolism
Oral semaglutide is the first oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) for type 2 diabetes mellitus, demonstrating significant benefits in glycaemic control and weight reduction versus active comparators in the PIONEER phase 3a RCT pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::728db70052047a3744dfc0582f44bc4c
https://doi.org/10.1111/dom.14453
https://doi.org/10.1111/dom.14453
Publikováno v:
Advances in Therapy
Introduction The aim of this study was to evaluate the glycemic control and safety of insulin degludec/insulin aspart (IDegAsp) co-formulation in Japanese patients with type 2 diabetes (T2D) in a real-world clinical setting, including elderly patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ae62457b3c46e0da9bc55451bc22d5
http://europepmc.org/articles/PMC7932946
http://europepmc.org/articles/PMC7932946
Autor:
Marc Evans, Abhishek Shankar Chandramouli, Mads Faurby, Kasper Sommer Matthiessen, Phillip Bredahl Mogensen, Subodh Verma
Publikováno v:
Diabetes, obesitymetabolism. 24(7)
To investigate the budget implications of treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus other glucose-lowering treatment (here termed 'standard of care' [SoC]) during 2012-2019.GLP-1 RA-naïve adults with type 2 diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5248959a9fd0c625884ccc37291288d7
https://pubmed.ncbi.nlm.nih.gov/35504854
https://pubmed.ncbi.nlm.nih.gov/35504854
Autor:
null Marc Evans, null Susanne Engberg, null Mads Faurby, null João Diogo Da Rocha Fernandes, null Pollyanna Hudson, null William Polonsky
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5896da06b3541cc77be4ad8ec9e99349
https://doi.org/10.1111/dom.14603/v2/response1
https://doi.org/10.1111/dom.14603/v2/response1
Autor:
William H. Polonsky, Marc Evans, Joao Diogo Da Rocha Fernandes, Susanne Engberg, Mads Faurby, Pollyanna Hudson
Publikováno v:
Diabetes, obesitymetabolism. 24(3)
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world non-interven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b984fe770b4ef3015828bbdd47f635ae
https://pubmed.ncbi.nlm.nih.gov/34779107
https://pubmed.ncbi.nlm.nih.gov/34779107
Publikováno v:
Diabetes Therapy
Introduction Reducing dosing frequency may lower treatment burden and improve persistence and adherence. This retrospective, observational study assessed persistence and adherence in patients with type 2 diabetes (T2D) initiating once-weekly or daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2aacbec658ce99336ac406aad1462b
https://pubmed.ncbi.nlm.nih.gov/34918213
https://pubmed.ncbi.nlm.nih.gov/34918213
Publikováno v:
Diabetes. 70
Introduction: Reducing dosing frequency may reduce treatment burden and improve adherence and persistence. We assessed persistence and adherence in patients with T2D initiating once-weekly (OW) or once-daily (OD) injectable glucagon-like peptide-1 re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab5891aa8eaecb5474786d11fe2fdf9e
https://doi.org/10.2337/db21-83-lb
https://doi.org/10.2337/db21-83-lb